| Treatment of relapsing polychondritis in the era of biological agents. | |
| | |
MedLine Citation:
|
PMID: 20020132 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Relapsing polychondritis (RP) is a rare disorder, often requiring high doses of immunosuppressive therapy to control its potentially life-threatening consequences. The advent of biological agents has added to the armamentarium available to treat RP, but the lack of controlled trials, along with the small numbers of patients and disease heterogeneity means that new therapies are prescribed without the benefits of rigorous clinical research. Thus, information on individual cases is of value in expanding our knowledge of the use of biologic agents in rare conditions. We report on the use of rituximab in a patient who subsequently developed catastrophic aortic incompetence, and we review the literature in relation to the use of this drug in RP. |
| | |
Authors:
|
Eoghan M McCarthy; Gaye Cunnane |
Publication Detail:
|
Type: Case Reports; Journal Article Date: 2009-12-18 |
Journal Detail:
|
Title: Rheumatology international Volume: 30 ISSN: 1437-160X ISO Abbreviation: Rheumatol. Int. Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-03-19 Completed Date: 2010-06-15 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8206885 Medline TA: Rheumatol Int Country: Germany |
Other Details:
|
Languages: eng Pagination: 827-8 Citation Subset: IM |
Affiliation:
|
Department of Rheumatology, St James' Hospital, Dublin 8, Ireland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
therapeutic use* Antirheumatic Agents / therapeutic use Aortic Valve / drug effects, pathology, surgery Aortic Valve Insufficiency / drug therapy*, immunology*, surgery Azathioprine / therapeutic use C-Reactive Protein / metabolism Cardiac Surgical Procedures Collagen / immunology Hearing Loss, Sensorineural / etiology, surgery Humans Immunity, Cellular / drug effects, immunology Immunosuppressive Agents / therapeutic use* Lymphocyte Activation / drug effects, immunology Male Middle Aged Polychondritis, Relapsing / complications*, drug therapy*, physiopathology Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Immunosuppressive Agents; 0/rituximab; 446-86-6/Azathioprine; 9007-34-5/Collagen; 9007-41-4/C-Reactive Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and peri...
Next Document: Validation of the World Health Organization disability assessment schedule II (WHODAS-II) in patient...